Cargando…
Assessing Histological Inflammatory Activity in Patients With Ulcerative Colitis: A Diagnostic Accuracy Study Testing Fecal Biomarkers Lactoferrin and Calprotectin
BACKGROUND AND AIMS: Histological remission has arisen as the optimal treatment outcome in ulcerative colitis (UC). The aim of this retrospective study was to explore the diagnostic performance of the noninvasive fecal biomarkers calprotectin (FC) and lactoferrin (FL) compared to the histological in...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802191/ https://www.ncbi.nlm.nih.gov/pubmed/36776494 http://dx.doi.org/10.1093/crocol/otaa053 |
_version_ | 1784861632776634368 |
---|---|
author | Langhorst, Jost Kairey, Lana Oberle, Angela Boone, James Dobos, Gustav Juette, Hendrik Tannapfel, Andrea Rueffer, Andreas |
author_facet | Langhorst, Jost Kairey, Lana Oberle, Angela Boone, James Dobos, Gustav Juette, Hendrik Tannapfel, Andrea Rueffer, Andreas |
author_sort | Langhorst, Jost |
collection | PubMed |
description | BACKGROUND AND AIMS: Histological remission has arisen as the optimal treatment outcome in ulcerative colitis (UC). The aim of this retrospective study was to explore the diagnostic performance of the noninvasive fecal biomarkers calprotectin (FC) and lactoferrin (FL) compared to the histological indices Nancy Index (NI) and Riley Index (RI). METHODS: This study is a retrospective diagnostic accuracy study based on secondary analysis of patient data from 2002 to 2017 extracted from medical registries of our clinics in Essen-Mitte, Germany. Patients with UC underwent a colonoscopy, with biopsies taken from the rectum and the sigmoid scored by 2 experienced pathologists according to NI and RI and provided a stool sample within 7 days pre- or post-colonoscopy. Diagnostic accuracy of recommended cutoffs for FC (>50 μg/g) and FL (≥7.25 μg/g) were tested against our reference standard (NI ≥2) in terms of specificity, sensitivity, positive predictive value, negative predictive value, and accuracy (effectiveness). RESULTS: The number of patients with UC recruited was n = 226, aged 45.2 (SD 13.3). Histological indices were highly correlated (r = 0.980, P < 0.001). Fecal biomarkers correlated moderately with NI (FC: r = 0.383, P < 0.001; FL: r = 0.420, P < 0.001) and RI (FC: r = 0.395, P < 0.001; FL: r = 0.424, P < 0.001). Fecal biomarker concentrations were increased in patients with active histological disease (NI ≥2), median [IQR], FC 69.72 [20.07–254.38], FL 18.59 [6.06–44.42], compared to those with inactive disease (NI ≤1), FC 12.35 [3.89 – 32.16], FL 3.14 [0.75–11.05], z = −6.60, P < 0.001. Fecal biomarker concentrations differed significantly across NI grades 0–4 (FC: H(4) = 45.2; FL: H(4) = 47.5, both P < 0.001). Patients with grade 0 had significantly lower concentrations of fecal biomarkers than those with grade 3 (median; FC 10.94 vs 72.22; FL 2.30 vs 29.10; both P < 0.001) or grade 4 (FC 10.94 vs 67.00; FL 2.30 vs 27.64; both P < 0.001), as well as grade 2 for FC only (10.94 vs 56.22, P = 0.001). Concentrations were also lower in patients with grade 1 compared to those with grade 3 (FC 17.49 vs 72.22; FL 4.24 vs. 29.10; both P ≤ 0.001) or grade 4 (FC 17.49 vs 67.00; FL 4.24 vs 27.64; both P < 0.001). Receiver operating characteristics area under the curve showed moderate diagnostic accuracy for both FC 0.76 (95% confidence interval [CI] 0.70–0.83) and FL 0.73 (95% CI 0.66–0.80). Optimized cutoffs for both FC (≥34.29) and FL (≥5.85 μg/g) had slightly improved accuracy, compared with the manufacturer’s cutoffs (FC: 69.9% vs 65.9%; FL: 71.7% vs 69.0%). CONCLUSIONS: Fecal biomarkers calprotectin and lactoferrin correlate with histological disease activity and differentiate between patients in histological remission from those with evidence of moderate to severe disease activity. Their noninvasiveness, in addition to being inexpensive, supports their use in the clinical monitoring of patients with UC. |
format | Online Article Text |
id | pubmed-9802191 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-98021912023-02-10 Assessing Histological Inflammatory Activity in Patients With Ulcerative Colitis: A Diagnostic Accuracy Study Testing Fecal Biomarkers Lactoferrin and Calprotectin Langhorst, Jost Kairey, Lana Oberle, Angela Boone, James Dobos, Gustav Juette, Hendrik Tannapfel, Andrea Rueffer, Andreas Crohns Colitis 360 Observations and Research BACKGROUND AND AIMS: Histological remission has arisen as the optimal treatment outcome in ulcerative colitis (UC). The aim of this retrospective study was to explore the diagnostic performance of the noninvasive fecal biomarkers calprotectin (FC) and lactoferrin (FL) compared to the histological indices Nancy Index (NI) and Riley Index (RI). METHODS: This study is a retrospective diagnostic accuracy study based on secondary analysis of patient data from 2002 to 2017 extracted from medical registries of our clinics in Essen-Mitte, Germany. Patients with UC underwent a colonoscopy, with biopsies taken from the rectum and the sigmoid scored by 2 experienced pathologists according to NI and RI and provided a stool sample within 7 days pre- or post-colonoscopy. Diagnostic accuracy of recommended cutoffs for FC (>50 μg/g) and FL (≥7.25 μg/g) were tested against our reference standard (NI ≥2) in terms of specificity, sensitivity, positive predictive value, negative predictive value, and accuracy (effectiveness). RESULTS: The number of patients with UC recruited was n = 226, aged 45.2 (SD 13.3). Histological indices were highly correlated (r = 0.980, P < 0.001). Fecal biomarkers correlated moderately with NI (FC: r = 0.383, P < 0.001; FL: r = 0.420, P < 0.001) and RI (FC: r = 0.395, P < 0.001; FL: r = 0.424, P < 0.001). Fecal biomarker concentrations were increased in patients with active histological disease (NI ≥2), median [IQR], FC 69.72 [20.07–254.38], FL 18.59 [6.06–44.42], compared to those with inactive disease (NI ≤1), FC 12.35 [3.89 – 32.16], FL 3.14 [0.75–11.05], z = −6.60, P < 0.001. Fecal biomarker concentrations differed significantly across NI grades 0–4 (FC: H(4) = 45.2; FL: H(4) = 47.5, both P < 0.001). Patients with grade 0 had significantly lower concentrations of fecal biomarkers than those with grade 3 (median; FC 10.94 vs 72.22; FL 2.30 vs 29.10; both P < 0.001) or grade 4 (FC 10.94 vs 67.00; FL 2.30 vs 27.64; both P < 0.001), as well as grade 2 for FC only (10.94 vs 56.22, P = 0.001). Concentrations were also lower in patients with grade 1 compared to those with grade 3 (FC 17.49 vs 72.22; FL 4.24 vs. 29.10; both P ≤ 0.001) or grade 4 (FC 17.49 vs 67.00; FL 4.24 vs 27.64; both P < 0.001). Receiver operating characteristics area under the curve showed moderate diagnostic accuracy for both FC 0.76 (95% confidence interval [CI] 0.70–0.83) and FL 0.73 (95% CI 0.66–0.80). Optimized cutoffs for both FC (≥34.29) and FL (≥5.85 μg/g) had slightly improved accuracy, compared with the manufacturer’s cutoffs (FC: 69.9% vs 65.9%; FL: 71.7% vs 69.0%). CONCLUSIONS: Fecal biomarkers calprotectin and lactoferrin correlate with histological disease activity and differentiate between patients in histological remission from those with evidence of moderate to severe disease activity. Their noninvasiveness, in addition to being inexpensive, supports their use in the clinical monitoring of patients with UC. Oxford University Press 2020-06-27 /pmc/articles/PMC9802191/ /pubmed/36776494 http://dx.doi.org/10.1093/crocol/otaa053 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Observations and Research Langhorst, Jost Kairey, Lana Oberle, Angela Boone, James Dobos, Gustav Juette, Hendrik Tannapfel, Andrea Rueffer, Andreas Assessing Histological Inflammatory Activity in Patients With Ulcerative Colitis: A Diagnostic Accuracy Study Testing Fecal Biomarkers Lactoferrin and Calprotectin |
title | Assessing Histological Inflammatory Activity in Patients With Ulcerative Colitis: A Diagnostic Accuracy Study Testing Fecal Biomarkers Lactoferrin and Calprotectin |
title_full | Assessing Histological Inflammatory Activity in Patients With Ulcerative Colitis: A Diagnostic Accuracy Study Testing Fecal Biomarkers Lactoferrin and Calprotectin |
title_fullStr | Assessing Histological Inflammatory Activity in Patients With Ulcerative Colitis: A Diagnostic Accuracy Study Testing Fecal Biomarkers Lactoferrin and Calprotectin |
title_full_unstemmed | Assessing Histological Inflammatory Activity in Patients With Ulcerative Colitis: A Diagnostic Accuracy Study Testing Fecal Biomarkers Lactoferrin and Calprotectin |
title_short | Assessing Histological Inflammatory Activity in Patients With Ulcerative Colitis: A Diagnostic Accuracy Study Testing Fecal Biomarkers Lactoferrin and Calprotectin |
title_sort | assessing histological inflammatory activity in patients with ulcerative colitis: a diagnostic accuracy study testing fecal biomarkers lactoferrin and calprotectin |
topic | Observations and Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802191/ https://www.ncbi.nlm.nih.gov/pubmed/36776494 http://dx.doi.org/10.1093/crocol/otaa053 |
work_keys_str_mv | AT langhorstjost assessinghistologicalinflammatoryactivityinpatientswithulcerativecolitisadiagnosticaccuracystudytestingfecalbiomarkerslactoferrinandcalprotectin AT kaireylana assessinghistologicalinflammatoryactivityinpatientswithulcerativecolitisadiagnosticaccuracystudytestingfecalbiomarkerslactoferrinandcalprotectin AT oberleangela assessinghistologicalinflammatoryactivityinpatientswithulcerativecolitisadiagnosticaccuracystudytestingfecalbiomarkerslactoferrinandcalprotectin AT boonejames assessinghistologicalinflammatoryactivityinpatientswithulcerativecolitisadiagnosticaccuracystudytestingfecalbiomarkerslactoferrinandcalprotectin AT dobosgustav assessinghistologicalinflammatoryactivityinpatientswithulcerativecolitisadiagnosticaccuracystudytestingfecalbiomarkerslactoferrinandcalprotectin AT juettehendrik assessinghistologicalinflammatoryactivityinpatientswithulcerativecolitisadiagnosticaccuracystudytestingfecalbiomarkerslactoferrinandcalprotectin AT tannapfelandrea assessinghistologicalinflammatoryactivityinpatientswithulcerativecolitisadiagnosticaccuracystudytestingfecalbiomarkerslactoferrinandcalprotectin AT ruefferandreas assessinghistologicalinflammatoryactivityinpatientswithulcerativecolitisadiagnosticaccuracystudytestingfecalbiomarkerslactoferrinandcalprotectin |